Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

January 26, 2024

Time Posted:2024-05-20 16:52

A novel inhaled anti-IL-4Rα monoclonal antibody has been introduced. This drug is also used to treat respiratory diseases such as asthma and COPD. Phase I clinical trials of the anti-IL-4Rα monoclonal antibody have been completed, and Phase II clinical trials have begun.

November 2023

Time Posted:2024-05-20 16:51

Introducing a highly selective second-generation Nav1.8 inhibitor, an innovative drug for pain treatment, expected to be highly effective and non-addictive. Health Yuan is responsible for subsequent clinical research and application for production of this drug.

November 2023

Time Posted:2024-05-20 16:51

Acquired rights to an anti-TSLP monoclonal antibody, a drug used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The anti-TSLP monoclonal antibody is currently undergoing Phase II clinical trials for asthma in China.

April 2023

Time Posted:2024-05-20 16:50

An exclusive license agreement for a new antiviral drug against influenza in Greater China has been reached. The new drug was submitted for production in August and is expected to be launched next year.

Jiankangyuan and Lizhu Group were awarded the "Special Contribution Award" and the "China Red Cross Medal of Love" by the China Red Cross Society.

Time Posted:2024-05-08 17:16

Recently, the Red Cross Society of China issued a notice on awarding medals and plaques to donors who have made outstanding contributions to the Chinese Red Cross cause in 2023. LiZhu Pharmaceutical Group Co., Ltd. and its parent company, Joincare Pharmaceutical Group Industry Co., Ltd., were awarded the "Special Contribution Award" and the "China Red Cross Charity Medal", respectively.

Health Yuan's innovative foundation: TG-1000 is about to be launched, achieving stable operation in the first quarter of 2024

Time Posted:2024-04-26 16:43

On the evening of April 25, 2024, Health Yuan (600380.SH), a leading manufacturer of respiratory drugs, disclosed its first-quarter performance. From January to March 2024, the company achieved operating revenue of 4.34 billion yuan and net profit attributable to shareholders of 440 million yuan. Sales of the company's key specialized respiratory products made a significant contribution to overall revenue, reaching 417 million yuan in the first quarter, accounting for 9.61% of total revenue.

Q1 Business Development Transaction Overview

Time Posted:2024-04-24 14:29

The first quarter of 2024 has passed quickly. This review summarizes the major business development (BD) transactions in the pharmaceutical field from January to March, providing insights into the current market situation and trends. Based on publicly available information from sources such as Meibai Capital and various listed company announcements, a total of 50 transactions were completed in the Chinese pharmaceutical sector this quarter. This includes 12 license-in transactions, 27 license-out transactions, and 11 domestic transactions. Compared to the 32 transactions in the first quarter of 2022, this represents a 56% increase. It has also been observed that 32 of these 50 transactions originated from information released at the J.P. Morgan Healthcare Conference in the United States at the beginning of 2024.

< 1...101112...55 >